CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Abstract Background Mast cell activation causes degranulation and release of cytokines, thereby promoting inflammation. The aim of this study was to investigate the inhibitory effect of CDK4/6 inhibition on mast cell activation in vitro and in vivo. Methods RBL-2H3 rat basophilic leukemia cells (BLC...
Main Authors: | Yi-Bo Hou, Kunmei Ji, Yue-Tong Sun, Li-Na Zhang, Jia-Jie Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-019-2026-9 |
Similar Items
-
The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
by: Lubaid Saleh, et al.
Published: (2023-04-01) -
Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01) -
Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells
by: Gregory T. Gallanis, et al.
Published: (2023-03-01) -
CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01) -
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
by: Carole Bandiera, et al.
Published: (2023-01-01)